Periodontitis, a highly prevalent multicausal chronic inflammatory and destructive disease, develops as a result of complex host-parasite interactions. Dysbiotic bacterial biofilm in contact with the gingival tissues initiates a cascade of inflammatory events, mediated and modulated by the host's immune response, which is characterized by increased expression of several inflammatory mediators such as cytokines and chemokines in the connective tissue. If periodontal disease (PD) is left untreated, it results in the destruction of the supporting tissues around the teeth, including periodontal li
Совпадение в полном тексте источника … Alendronate was administered intravenously for 16 weeks, and clinical and radiographical analyses were performed. The authors demonstrated that 0.05 mg/kg alendronate treatment reduced the progression of PD, suggesting its use to treat PD. … The authors pointed out that using alendronate to treat experimental PD in rats might increase the risk of ONJ development.
The use of alendronate as adjunctive to scaling and root planning (SRP) in rats with induced PD was evaluated by De Almeida et al. [ 35 ]. …
Полный текст найденПеревод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
BACKGROUND: The aim of the present work was to analyze a 10-year retrospective series of surgically treated medication-related osteonecrosis of the jaws (MRONJ) cases, reporting the clinical outcome and success rate for each adopted procedure in order to draw a treatment algorithm that is able to standardize clinical decision making and maximize the success of oral surgical treatment of MRONJ.
METHODS: Different surgical approaches were categorized taking into consideration two variables a) hard tissue management (defined as debridement, saucerization or marginal resective surgery of maxillar
Совпадение в полном тексте источника … Two patients consumed alendronate and risedronate consecutively, and two were treated with alendronate followed by ibandronate. One patient with osteoporosis adopted a step-down therapy, switching from zoledronate to risedronate. One patient was treated with zoledronate followed by denosumab 60 mg. … (i.v) | 52.5
Zoledronate (i.v) + Ibandronate (per os) | 65
Alendronate (per os) + Risedronate (per os) | 85.5
Alendronate (per os) + Ibandronate (per os) | 164.5
Neridronate (i.v) + Ibandronate (per os) | 70
Zoledronate (i.v) + Denosumab 120 mg (subcutaneous) | 24
Zoledronate (i.v) + Denosumab 60 mg …
Полный текст найденПеревод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Antiresorptive therapy is the main form of prevention of osteoporotic or fragility fractures. Medication-related osteonecrosis of the jaw (MRONJ) is a relatively rare but severe adverse reaction to antiresorptive and antiangiogenic drugs. Physicians and dentists caring for patients taking these drugs and requiring invasive procedures face a difficult decision because of the potential risk of MRONJ. The aim of this study was to discuss the risk factors for the development of MRONJ and prevention of this complication in patients with osteoporosis taking antiresorptive drugs and requiring invasiv
Совпадение в полном тексте источника … A longitudinal cohort of 61,990 users of alendronate followed up for a mean period of 6.8 years identified 107 cases of MRONJ and showed that recent compared with past use of alendronate was associated with an adjusted odds ratio of 4.13 (95% confidence interval [CI] 1.94-8.79) ( 20 ). … Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users. …
Полный текст найденПеревод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
BACKGROUND: Despite advances in the diagnosis of oral squamous cell carcinoma (OSCC), most cases are diagnosed in advanced stages, influencing negatively the patient's prognosis. The absence of specific signs and symptoms contributes to the diagnostic delay of OSCC, often leading to confusion with various oral conditions, including, in patients with a history of bone modifying agents (BMA) and/or anti-angiogenic (AA) molecules, the Medication-Related Osteonecrosis of the Jaw (MRONJ). This study aims to investigate the characteristics of OSCC and MRONJ, focusing on clinical and radiological fea
Совпадение в полном тексте источника … Case #2
A 72-year-old non-smoker woman with osteoporosis was treated with alendronate for more than 10 years (once-weekly oral alendronate 70 mg). Five months before the examination, she underwent dental extraction of teeth 3.6 and 3.7. … Additionally, she was affected by chronic drug-induced pancreatitis and osteoporosis, and she had been treated from 2016 to 2018 with alendronate (once-weekly oral alendronate 70 mg), and steroids. …
Полный текст найденПеревод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
BACKGROUND: Osteoporosis is a chronic, systemic skeletal disease characterized by decreased bone mass and microarchitectural deterioration, leading to increased fracture risk. In Slovakia, its prevalence is estimated at 6%, with substantial health, social, and economic burdens.
OBJECTIVE: The Slovak national guideline provides an overview for the diagnosis, prevention, and treatment of osteoporosis in Slovakia, reflecting recent scientific advances and recommendations from international bodies.
METHODS: The guidelines were developed by a multidisciplinary expert panel and officially adopted
Совпадение в полном тексте источника … The potential for inhibition of farnesyl pyrophosphate synthase decreases in the order “zoledronate > risedronate ˃ ibandronate ˃ alendronate.”
Alendronate, risedronate, ibandronate, and zoledronic acid are indicated in the treatment of postmenopausal osteoporosis. … Significantly greater risk reduction in new vertebral and clinical fractures was seen for romosozumab vs. alendronate at 12 months [ 24 ]. …
Полный текст найденПеревод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fragility fractures are a major complication in chronic kidney disease (CKD), yet therapeutic strategies for their prevention remain highly controversial. The unique pathophysiology of CKD-mineral and bone disorder (CKD-MBD), coupled with the paucity of dedicated clinical trials, create substantial uncertainty regarding the efficacy and safety of medical interventions established in the general osteoporosis population. This review summarizes the available evidence regarding fracture risk and bone mineral density including pragmatic clinical guidance for the use of calcium, vitamin D, phosphate
Совпадение в полном тексте источника … There is one recent case report documenting collapsing FSGS with AKI and nephrotic syndrome after oral alendronate 70 mg weekly [ 121 ]. … Among participants with CKD stage 3, relative risk of new vertebral fractures was 72% (95% CI, 14–91; p = 0.017) compared to placebo and 51% (95% CI, 5–75; p = 0.04) compared to alendronate [ 150 ]. …
Полный текст найденПеревод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Osteoporosis is a major health concern, which results in the increased risk of fractures. There is a high risk for the first or consecutive fractures leading to considerable morbidity and debilitating consequences if osteoporosis is untreated. Currently, bisphosphonates are the mainstay of treatment for osteoporosis though long-term persistence and adherence to bisphosphonates, especially those taken orally, remain low. This medication noncompliance has serious consequences on osteoporotic patients as it is associated with a significantly higher fracture risk. Intravenous (IV) zoledronic acid
Совпадение в полном тексте источника … Weekly administration of alendronate: rationale and plan for clinical assessment. Clin Ther. 2000;22(1):15–28. doi: 10.1016/s0149-2918(00)87974-6.
84. Schnitzer T, Bone HG, Crepaldi G, et al. … Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 2000;12:1–12.
85. Brown JP, Kendler DL, McClung MR, et al. …
Полный текст найденПеревод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Infection with the human immunodeficiency virus-1 (HIV) and the resulting acquired immune deficiency syndrome (AIDS) alter not only cellular immune regulation but also the bone metabolism. Since cellular immunity and bone metabolism are intimately intertwined in the osteoimmune network, it is to be expected that bone metabolism is also affected in patients with HIV/AIDS. The concerted evidence points convincingly toward impaired activity of osteoblasts and increased activity of osteoclasts in patients with HIV/AIDS, leading to a significant increase in the prevalence of osteoporosis. Research
Совпадение в полном тексте источника … Alendronate and etidronate were as cost-effective alternatives for treating women with osteoporosis, although the model did not permit long-term projection [ 92 ]. … The extensive and focused nature of the systematic review yielded three RCT studies that reported examination of the role of alendronate in patients with HIV and osteopenia or osteoporosis. …
Полный текст найденПеревод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
ObjectivesBisphosphonate-related osteonecrosis of the jaw (BRONJ) is a relatively rare but serious side effect of bisphosphonate (BP)-based treatments. This retrospective study aimed to investigate the risk factors and predictive markers in cases where patients were refractory to a recommended conservative treatment offered in our hospital.Patients and methodsThis single-center study collated the medical records of all patients treated for BRONJ between 2004 and 2011. A complete medical history, including detailed questionnaires, was collected for all patients, focusing on identifying underlyi
Совпадение в полном тексте источника … In our department, second generation BPs such as alendronate accounted for half of all BRONJ patients (stage 0–3). … In this study, alendronate accounted for 33% of refractory cases, suggesting that a large number of BRONJ cases induced by oral BPs are resistant to conservative treatment. …
Полный текст найденПеревод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2012eng
UnlabelledDrugs used for the prevention and the treatment of osteoporosis exert various favourable and unfavourable extra-skeletal effects whose importance is increasingly recognized notably for treatment selection.IntroductionThe therapeutic armamentarium for the prevention and the treatment of osteoporosis is increasingly large, and possible extra-skeletal effects of available drugs could influence the choice of a particular compound.MethodsThe present document is the result of a national consensus, based on a systematic and critical review of the literature.ResultsObservational research has
Совпадение в полном тексте источника … Post hoc analyses of previous main trials on alendronate, risedronate and ibandronate having involved about 30,000 patients did not show any clear-cut association with atrial fibrillation [ 164 – 166 ]. … On the other hand, there was no difference in the rates of venous thromboembolism in the samples of women with osteoporosis (no treatment, strontium ranelate or alendronate). …
Полный текст найденПеревод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Neridronate is an aminobisphosphonate, licensed in Italy for the treatment of osteogenesis imperfecta (OI) and Paget's disease of bone (PDB). A characteristic property of neridronate is that it can be administered both intravenously and intramuscularly, providing a useful system for administration in homecare. In this review, we discuss the latest clinical results of neridronate administration in OI and PDB, as well as in osteoporosis and other conditions. We will focus in particular on the latest evidence of the effect of neridronate on treatment of complex regional pain syndrome type I.
Совпадение в полном тексте источника … Namely, a comparison between oral alendronate and intravenous pamidronate proved that bisphosphonates had similar efficacy in achieving biochemical remission in previously untreated patients, but in those who had formerly been treated with pamidronate, alendronate was more effective. 24 In two other … A single intravenous infusion of 7.5 mg alendronate, 40 intravenous clodronate (300 mg for 10 days), 41 intravenous pamidronate (60 mg once), 42 and 40 mg daily oral alendronate for 12–16 weeks 43 have been reported to be associated with positive results in controlling pain, edema, and functional impairment …
Полный текст найденПеревод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
AIM: Medication-related osteonecrosis of the jaw (MRONJ) occurs after exposure to medication (antiresorptive or antiangiogenic agents) for bone-related complications. It is more common in the mandible than in the maxilla. The present study investigated maxillary MRONJ in elderly patients through a meta-analysis.
METHODS: Keywords, including "MRONJ", "maxilla", and "surgery", were entered into databases, including Embase, PubMed/MEDLINE, Cochrane Library, and ProQuest, which were searched systematically.
RESULTS: Investigating 77 studies, we found that 18 (2 case reports and 16 case series) p
Совпадение в полном тексте источника … The treatment of osteoporosis relies largely on bisphosphonates (BPs; mainly alendronate sodium (Fosamax ® , Merck Sharp & Dohme Ltd., Kenilworth, NJ, USA)) and ibandronate (Boniva ® , Roche Products Ltd., Basel, Switzerland) and denosumab, which inhibit osteoclast-mediated bone resorption to prevent … Regarding medication, 79.1% of patients were taking bisphosphonates during the treatment period, with the most frequently administered being zoledronate (35.6%), followed by alendronate (10.2%), ibandronate (6.1%), risedronic acid (3.2%), and pamidronate (2.9%). …
Полный текст найденПеревод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
A temporary discontinuation (drug holiday) of high-dose antiresorptive (AR) agents has been proposed to reduce the risk of medication-related osteonecrosis of the jaw (MRONJ). The aim of this systematic review was to answer the question: Is high-dose AR drug holiday, at the time of tooth extraction or dentoalveolar surgery, necessary to prevent the development of MRONJ in patients with cancer? This protocol was registered in the PROSPERO database. Medline, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched for relevant studies up to and including April 2019.
Совпадение в полном тексте источника … AR agents are used in low doses (e.g., Alendronate, Aclasta, Prolia) to treat osteoporosis, and in a high dose (e.g., Zometa, Pamifos, Xgeva) to manage cancer-related conditions. In recent years, AR agents have also been used as adjuvant therapies for patients with cancer [ 1 ]. … (2/33), Zoledronate + Alendronate (1/33) | I.v. treatment: 26.3 (mean) (2 patients with Alendronate for 10 years) | Extractions (16/33), Implant treatment (3/33), Periodontal disease (9/33), Misfitting dentures (8/33), Palatal tori (2/33), Spontaneous onset (8/33) | 2 (37/46), 3 (9/46) | All surgically …
Полный текст найденПеревод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Osteoporosis is a skeletal pathology characterized by compromised bone strength leading to increased risk of fracture, mainly the spine and hip fractures. Osteoporosis affects more than 200 million people worldwide and because of the skeletal fractures it causes, represents a major cause of morbidity, disability and mortality in older people. Recently, the new discoveries of osteoimmunology have clarified many of the pathogenetic mechanisms of osteoporosis, helping to identify new immunological targets for its treatment opening the way for new and effective therapies with biological drugs. Cur
Совпадение в полном тексте источника … The ARCH study is a head-to-head comparative study between romosozumab and alendronate mono-therapy for one year and therefore sequential therapy with alendronate in both groups, with fractures as the primary endpoint. … This is probably due to the alendronate-mediated strengthening of the indirect antiresorbing action of romosozumab, as suggested by the suppression of bone turnover markers by alendronate [ 57 ]. …
Полный текст найденПеревод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
In this consensus paper, the Belgian Bone Club aims to provide a state of the art on the epidemiology, diagnosis, and management of osteoporosis in frail individuals, including patients with anorexia nervosa, patients on dialysis, cancer patients, persons with sarcopenia, and the oldest old. All these conditions may indeed induce bone loss that is superimposed on physiological bone loss and often remains under-recognized and under-treated. This is of particular concern because of the major burden of osteoporotic fractures in terms of morbidity, mortality, and economic cost. Therefore, there is
Совпадение в полном тексте источника … After 3 years, alendronate significantly reduced the risk of vertebral fracture by 38% (RR 0.62; 95% CI 0.41–0.94) in women aged ≥75 years compared to 51% in the younger age group (RR 0.49; 95% CI 0.35–0.68). … Finally, also a very recent study showed that alendronate in patients older than 80 years who had a prior fracture was associated with a reduced hip fracture risk (HR 0.72; 95% CI 0.61–0.85) [ 92 ]. …
Полный текст найденПеревод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
BACKGROUND: This article explores the mechanism of action of atypical femoral fractures (AFF), specifically focussing on osteoporosis, management challenges, and the implications for clinical practice. Non-union of AFF can result in severe pain, deformity and restricted mobility-all of which will have a detrimental impact on the patients' quality of life.
PURPOSE: This review consolidates the current literature regarding non-union after bisphosphonate-associated atypical femoral fractures, providing a revision tool for higher examinations.
METHOD/FINDINGS: An extensive search strategy was co
Совпадение в полном тексте источника … In a report conducted by Odvina et al. [ 37 ] 9 subjects were identified who had sustained spontaneous non-spinal fractures while on alendronate therapy. … Kwek EBK et al (2008) An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 39(2):224–231. 10.1016/j.injury.2007.08.036
27. Wang K et al (2011) Alendronate-associated femoral insufficiency fractures and femoral stress reactions. …
Полный текст найденПеревод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Osteoporosis, a chronic metabolic bone disease, increases the predisposition to fragility fractures and is associated with considerable morbidity, high health care cost as well as mortality. An elevation in the rate of incident fragility fractures will be observed proportional with the increase in the number of older people worldwide. Severe osteoporosis is currently defined as having a bone density determined by dual-energy X-ray absorptiometry that is more than 2.5 standard deviations (SD) below the young adult mean with one or more past fractures due to osteoporosis. Nutrition, physical act
Совпадение в полном тексте источника … The 2017 ARCH study compared postmenopausal women treated with alendronic acid for 24 months against women who received romosozumab for 12 months followed by alendronic acid for another 12 months. … Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350(12):1189–99. 10.1056/NEJMoa030897.
106. Kendler D, Chines A, Clark P, Ebeling PR, McClung M, Rhee Y, Huang S, Stad RK. Bone mineral density after transitioning from denosumab to alendronate. …
Полный текст найденПеревод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Study DesignRetrospective Cohort Study.ObjectiveThe primary objective of this study is to evaluate the efficacy of early administration of Teriparatide in preventing the necessity of surgical intervention in individuals with osteoporotic vertebral compression fractures.MethodsIn a 24-month follow-up retrospective analysis, 191 OVCF patients from January 2016 to October 2020 were randomly assigned to Non teriparatide Group A (n = 104) or Group B teriparatide (n = 87). At baseline, 6 months, 1 year, and 2 years following treatment, demographic data and need of surgical intervention, VAS, ODI, un
Совпадение в полном тексте источника … Group A was administered Alendronate sodium 70 mg once weekly, while Group B (TTPD) got a daily subcutaneous injection of Teriparatide (20 μg/day) in addition to Alendronate sodium 70 mg weekly both for 18 months. … A retrospective study done in 2021 on OVCF patients treated with teriparatide and alendronate showed that the area of bone mineralization in the teriparatide group (54.28%) was significantly higher than that of patients treated with alendronate (35.57%). 15 A meta-analysis done in 2021 showed that teriparatide …
Полный текст найденПеревод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
BACKGROUND: Osteoporosis-associated fractures are of increasing importance in trauma surgery. Systematic diagnostics and treatment of osteoporosis during a hospital stay, however, remain inadequate. Therefore, a specific algorithm for diagnosing and treating osteoporosis in trauma surgery patients was developed based on the DVO (German Osteology Society) guideline for osteoporosis from 2014.
METHODS: In a first step, the individuals' age and risk profile for osteoporosis is identified considering specific fractures indicating osteoporosis and risk factors assessed by a specific questionnaire.
Совпадение в полном тексте источника … Table 2
Approval status of selected drugs for specific treatment of osteoporosis
a Men with decreased bone density and higher risk of fractures
Compound | Post-menopausal women | Men >60 years
Alendronate 70 mg/week | X | –
Alendronate 10 mg/day | X | X
Risedronate 35 mg/week | X | X
Ibandronate oral … Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther. 1995;58(3):288–98. doi: 10.1016/0009-9236(95)90245-7.
46. Abrahamsen B, Eiken P, Eastell R. Proton pump inhibitor use and the antifracture efficacy of alendronate. …
Полный текст найденПеревод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
OBJECTIVE: To compare incidence of first osteoporotic fracture in two cohorts of postmenopausal women, one treated with bisphosphonates and the other only with calcium and vitamin D.
DESIGN: Retrospective population cohort study with paired matching based on data from electronic health records.
SETTING: Women aged 60 years and older in 2005, from 21 primary care centers in a healthcare region of Spain.
PARTICIPANTS: Two groups of women aged 60 years and older (n = 1208), prescribed either calcium and vitamin D (CalVitD) or bisphosphonates (BIPHOS) with or without calcium and vitamin D, were
Совпадение в полном тексте источника … However, a significantly lower incidence of radiological vertebral fractures was observed in the group treated with alendronate [ 32 ]. … Optimización del tratamiento con alendronate en osteoporosis [Improvement of treatment with alendronate in osteoporosis]. Universidad Complutense de Madrid. 2009; Available: http://eprints.ucm.es/8891/1/T30917.pdf . Accessed 04 April 2014
18. Sanfelix-Gimeno G. …
Полный текст найденПеревод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
MedElevator
Войти в исследования